The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers

Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer

(2021) Alessandro Rizzo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD‐1/PD‐L1 Blockade Responses

(2021) Jihoon G. Yoon et al.   HEPATOLOGY

Blood tests predict the therapeutic prognosis of anti‐PD‐1 in advanced biliary tract cancer

(2021) Fei Du et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

(2020) Sarina A. Piha-Paul et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

(2020) Do-Youn Oh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.

(2020) Eric Xueyu Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

(2020) Richard D. Kim et al.   JAMA Oncology

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

(2020) Changhoon Yoo et al.   Journal for ImmunoTherapy of Cancer

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers

(2020) Oliver Klein et al.   JAMA Oncology

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies

(2020) Anita Mazloom et al.   Journal of Clinical Medicine

Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

(2020) Jianzhen Lin et al.   Hepatobiliary Surgery and Nutrition

Molecular profile of BRCA-mutated biliary tract cancers

(2020) Gilbert Spizzo et al.   ESMO Open

Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers

(2020) Wei Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look

(2020) Angela Dalia Ricci et al.   Cancer Control

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

(2019) Tatsuya Ioka et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

(2019) Makoto Ueno et al.   Lancet Gastroenterology & Hepatology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

(2018) Hendrik‐Tobias Arkenau et al.   ONCOLOGIST

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

(2018) Robin Kate Kelley et al.   JOURNAL OF CLINICAL ONCOLOGY

625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study

(2018) M Ueno et al.   ANNALS OF ONCOLOGY

The role of tumour microenvironment: a new vision for cholangiocarcinoma

(2018) Ziyan Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

(2014) Atsushi Aruga et al.   Journal of Translational Medicine

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma

(2014) Omar Hyder et al.   JAMA Surgery

Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma

(2011) Koichi Shimizu et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

(2010) Miho Kaida et al.   JOURNAL OF IMMUNOTHERAPY